Seres therapeutics announces vowst™ commercial launch update and us fda fast track designation for ser-155

Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb), a leading microbiome therapeutics company, today announced preliminary key vowst (fecal microbiota spores, live-brpk) launch metrics and receipt of us fda fast track designation for ser-155 ahead of its presentation at the 42nd annual j.p. morgan healthcare conference on wednesday, january 10th. vowst, the first fda approved orally administered microbiome therapeutic, received fda approval in april of 2023 and is indica.
MCRB Ratings Summary
MCRB Quant Ranking